FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306174630> ?p ?o ?g. }

• W4306174630 abstract "Polo-like kinase 4 (PLK4) promotes tumorigenesis and is associated with the prognosis of several solid tumors, while its clinical role in patients with renal cell carcinoma (RCC) remains unidentified. The present study aimed to analyze the association of PLK4 with clinicopathological characteristics and long-term prognosis in patients with RCC. The present study detected PLK4 protein and mRNA expression using immunohistochemical and reverse transcription-quantitative PCR assays in 120 patients with RCC. Disease-free survival (DFS) and overall survival (OS) time were calculated based on a median follow-up duration of 6.9 years (range, 1.2-9.9 years). PLK4 protein expression was elevated in tumor tissues compared with adjacent tissues (P<0.001). Upregulation of PLK4 protein was associated with increased T stage (P=0.023), N stage (P=0.014) and TNM stage (P=0.007). Additionally, elevated tumor PLK4 protein expression exhibited an associating trend (without statistical significance) with reduced DFS rate (P=0.066) and was associated with decreased OS rate (P=0.036). However, univariate Cox's regression analysis indicated that high PLK4 protein expression (compared with low PLK4 protein expression) was associated with reduced OS rate (P=0.040) but not with PFS rate (P=0.070). Following adjustment by multivariate Cox's regression analysis, PLK4 protein expression was associated with neither DFS nor OS rate (both P>0.050). Additionally, PLK4 mRNA expression was further detected in some patients (for which fresh specimens frozen in liquid nitrogen were available) to validate the aforementioned observations, and the expression was elevated in tumor tissues compared with adjacent tissues. Furthermore, increased PLK4 mRNA expression was associated with tumor size ≥7 cm, high TNM stage and reduced DFS rate (all P<0.050). PLK4 possesses a certain clinical utility in monitoring the clinical stage of patients with RCC, while its prognostic value requires further validation." @default.
• W4306174630 created "2022-10-14" @default.
• W4306174630 creator A5001136929 @default.
• W4306174630 creator A5006397807 @default.
• W4306174630 creator A5032694679 @default.
• W4306174630 creator A5041239331 @default.
• W4306174630 creator A5064503684 @default.
• W4306174630 date "2022-10-14" @default.
• W4306174630 modified "2023-10-04" @default.
• W4306174630 title "Aberrant expression of polo‑like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long‑term survival" @default.
• W4306174630 cites W1994545169 @default.
• W4306174630 cites W2019075495 @default.
• W4306174630 cites W2049708854 @default.
• W4306174630 cites W2076668534 @default.
• W4306174630 cites W2079481706 @default.
• W4306174630 cites W2091093281 @default.
• W4306174630 cites W2095750516 @default.
• W4306174630 cites W2107277218 @default.
• W4306174630 cites W2124957911 @default.
• W4306174630 cites W2192080449 @default.
• W4306174630 cites W2552702441 @default.
• W4306174630 cites W2802145014 @default.
• W4306174630 cites W2889178940 @default.
• W4306174630 cites W2901068426 @default.
• W4306174630 cites W2904516395 @default.
• W4306174630 cites W2913370688 @default.
• W4306174630 cites W2963449514 @default.
• W4306174630 cites W2965492852 @default.
• W4306174630 cites W2971901660 @default.
• W4306174630 cites W2997800678 @default.
• W4306174630 cites W3025451213 @default.
• W4306174630 cites W3044285031 @default.
• W4306174630 cites W3115566342 @default.
• W4306174630 cites W3119556397 @default.
• W4306174630 cites W3128646645 @default.
• W4306174630 cites W3136825371 @default.
• W4306174630 cites W3162370792 @default.
• W4306174630 cites W3188049662 @default.
• W4306174630 cites W3211158218 @default.
• W4306174630 cites W4200228450 @default.
• W4306174630 cites W4205097549 @default.
• W4306174630 cites W4213446786 @default.
• W4306174630 cites W4220959942 @default.
• W4306174630 cites W4221001983 @default.
• W4306174630 cites W4226325652 @default.
• W4306174630 doi "https://doi.org/10.3892/ol.2022.13547" @default.
• W4306174630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36311683" @default.
• W4306174630 hasPublicationYear "2022" @default.
• W4306174630 type Work @default.
• W4306174630 citedByCount "0" @default.
• W4306174630 crossrefType "journal-article" @default.
• W4306174630 hasAuthorship W4306174630A5001136929 @default.
• W4306174630 hasAuthorship W4306174630A5006397807 @default.
• W4306174630 hasAuthorship W4306174630A5032694679 @default.
• W4306174630 hasAuthorship W4306174630A5041239331 @default.
• W4306174630 hasAuthorship W4306174630A5064503684 @default.
• W4306174630 hasBestOaLocation W43061746301 @default.
• W4306174630 hasConcept C10515644 @default.
• W4306174630 hasConcept C121608353 @default.
• W4306174630 hasConcept C126322002 @default.
• W4306174630 hasConcept C142724271 @default.
• W4306174630 hasConcept C143998085 @default.
• W4306174630 hasConcept C144301174 @default.
• W4306174630 hasConcept C146357865 @default.
• W4306174630 hasConcept C151730666 @default.
• W4306174630 hasConcept C204232928 @default.
• W4306174630 hasConcept C2776283816 @default.
• W4306174630 hasConcept C2777472916 @default.
• W4306174630 hasConcept C2781018059 @default.
• W4306174630 hasConcept C29537977 @default.
• W4306174630 hasConcept C38180746 @default.
• W4306174630 hasConcept C502942594 @default.
• W4306174630 hasConcept C50382708 @default.
• W4306174630 hasConcept C555283112 @default.
• W4306174630 hasConcept C67082663 @default.
• W4306174630 hasConcept C71924100 @default.
• W4306174630 hasConcept C86803240 @default.
• W4306174630 hasConceptScore W4306174630C10515644 @default.
• W4306174630 hasConceptScore W4306174630C121608353 @default.
• W4306174630 hasConceptScore W4306174630C126322002 @default.
• W4306174630 hasConceptScore W4306174630C142724271 @default.
• W4306174630 hasConceptScore W4306174630C143998085 @default.
• W4306174630 hasConceptScore W4306174630C144301174 @default.
• W4306174630 hasConceptScore W4306174630C146357865 @default.
• W4306174630 hasConceptScore W4306174630C151730666 @default.
• W4306174630 hasConceptScore W4306174630C204232928 @default.
• W4306174630 hasConceptScore W4306174630C2776283816 @default.
• W4306174630 hasConceptScore W4306174630C2777472916 @default.
• W4306174630 hasConceptScore W4306174630C2781018059 @default.
• W4306174630 hasConceptScore W4306174630C29537977 @default.
• W4306174630 hasConceptScore W4306174630C38180746 @default.
• W4306174630 hasConceptScore W4306174630C502942594 @default.
• W4306174630 hasConceptScore W4306174630C50382708 @default.
• W4306174630 hasConceptScore W4306174630C555283112 @default.
• W4306174630 hasConceptScore W4306174630C67082663 @default.
• W4306174630 hasConceptScore W4306174630C71924100 @default.
• W4306174630 hasConceptScore W4306174630C86803240 @default.
• W4306174630 hasIssue "6" @default.
• W4306174630 hasLocation W43061746301 @default.
• W4306174630 hasLocation W43061746302 @default.

• next